Nearly 50 percent of colorectal cancer survivors have continued pain interference
the ONA take:
According to a recent study published in the journal Pain Medicine, researchers from the University of Alabama at Birmingham have found that almost half of colorectal cancer survivors with pain interference during the initial phase of care have continued pain interference after treatment.
For the study, researchers analyzed survey results from participants with colorectal cancer of the Cancer Care Outcomes Research and Surveillance Consortium during the initial phase of care and follow-up.
They identified 2,961 patients during the initial phase and 2,303 patients during follow-up. Results showed that at baseline, 24.7% of participants reported moderate and high pain interference compared with 23.7% during follow-up.
For 46% of participants with baseline pain interference, pain interference was either the same or worse at follow-up.
Researchers found that chemotherapy, comorbidities, depression, female gender, and radiation were associated with moderate and high pain interference at the time of diagnosis and during follow-up. On the other hand, older age was associated with improved pain interference.
The study also showed that those pulmonary disease or heart failure comorbidities had equivalent or increasing pain interference at follow-up.
Almost half of colorectal cancer survivors with pain interference during the initial phase of care have continued pain.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|